Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Frederick Ausubel

Massachusetts Eye and Ear Infirmary, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Octagon Therapeutics

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Ausubel is a founder of Octagon Therapeutics, a private company specialized in developing anti-infectives. The research project above involves using C. elegans–MRSA and C. elegans-VRE infection models to identify novel “druggable” targets and to develop novel antimicrobial compounds. The research results from this project could affect the value of the technology being developed by this company. The Partners Committee on Outside Activities review panel evaluated Dr. Ausubel’s financial interest in connection with the research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.

Listed Research Project
Harvard-wide Program on Antibiotic Resistance

Narrative Antibiotic resistance is a foremost public health concern worldwide. The Harvard-wide Program on Antibiotic Resistance, which has as its goal to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection, was specifically designed to be responsive to this global urgency. A highly productive multidisciplinary team will function collaboratively to capitalize on many advances it has already made to achieve this goal. � �

Filed on April 10, 2018.

Tell us what you know about Frederick Ausubel's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Frederick Ausubel Massachusetts Eye and Ear Infirmary Conflict of Interest Genma Biosciences Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page